- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 20.01. | New Oxford research institute established to tackle antimicrobial resistance | ||
| 20.01. | David Eatwell joins Porterhouse Insights | ||
| 20.01. | Relics from the past | ||
| 19.01. | EU proposes vaccine-sharing mechanism with low-income countries | ||
| 19.01. | Valneva set to begin commercial manufacturing of COVID-19 vaccine within days | ||
| 19.01. | WHO's director-general deems vaccine nationalism a "catastrophic moral failure" | ||
| 19.01. | Lilly partners with Merus on development of bispecific antibodies for cancer | ||
| 19.01. | GSK's PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours | ||
| 19.01. | Sourcing R&D innovation: why pharma companies need to evolve their business models | ||
| 18.01. | Research Partnership appoints Hannah Osborn to MedTech director role | ||
| 18.01. | Pfizer, BioNTech temporarily slow down shipments of COVID-19 vaccine to EU | ||
| 18.01. | NHS is set to begin offering COVID-19 vaccinations to over-70s this week | ||
| 18.01. | Cambridge University develops DNA test for secondary infections in COVID-19 patients | ||
| 18.01. | The search for effective drug treatments for COVID-19 | ||
| 15.01. | New hire and promotions announced at Evoke KYNE | ||
| 15.01. | Amgen strikes $240m autoimmune deal with Evoq Therapeutics | ||
| 15.01. | UK pharmacies to begin administering COVID-19 vaccinations | ||
| 15.01. | PHE study finds people who have had COVID-19 can still transmit the virus | ||
| 15.01. | New dosing option for AZ's Imfinzi approved in the EU and UK | ||
| 15.01. | 2021: the year of decentralisation in drug development | ||
| 14.01. | Bayer's finerenone scores FDA priority review for chronic kidney disease | ||
| 14.01. | New executive appointments at Synergy Vision | ||
| 14.01. | J&J could launch its single-dose COVID-19 vaccine in March | ||
| 14.01. | Celltrion's investigational mAb cuts COVID-19 recovery time | ||
| 14.01. | Takeda and KSQ Therapeutics to develop immune-based cancer treatments |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
